Public Employees Retirement System of Ohio Increases Holdings in Becton, Dickinson and Company $BDX

Public Employees Retirement System of Ohio increased its position in Becton, Dickinson and Company (NYSE:BDX) by 9.9% during the first quarter, HoldingsChannel.com reports. The fund owned 128,930 shares of the medical instruments supplier’s stock after acquiring an additional 11,633 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Becton, Dickinson and Company were worth $20,272,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BDX. Compound Planning Inc. grew its holdings in Becton, Dickinson and Company by 22.5% in the first quarter. Compound Planning Inc. now owns 3,536 shares of the medical instruments supplier’s stock valued at $556,000 after purchasing an additional 649 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Becton, Dickinson and Company by 19.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,002,375 shares of the medical instruments supplier’s stock worth $157,603,000 after buying an additional 162,521 shares during the last quarter. Inceptionr LLC purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $745,000. Sei Investments Co. boosted its position in shares of Becton, Dickinson and Company by 13.7% in the 1st quarter. Sei Investments Co. now owns 303,582 shares of the medical instruments supplier’s stock worth $47,729,000 after buying an additional 36,488 shares in the last quarter. Finally, MWA Asset Management grew its stake in Becton, Dickinson and Company by 53.1% in the 1st quarter. MWA Asset Management now owns 7,478 shares of the medical instruments supplier’s stock valued at $1,176,000 after acquiring an additional 2,593 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $156.26 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The firm has a market capitalization of $43.06 billion, a P/E ratio of 39.56, a P/E/G ratio of 11.06 and a beta of 0.21. The business’s 50-day simple moving average is $149.95 and its 200-day simple moving average is $164.97.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the company earned $3.35 EPS. The company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were given a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,188 shares of company stock worth $765,120. Insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on BDX. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Royal Bank Of Canada set a $175.00 price target on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Finally, Piper Sandler dropped their price objective on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $180.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.